St. Jude Medical has announced it has received FDA approval of its Assura portfolio of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators, according to a news release.
The company said the new implantable defibrillators feature SecureSense RV lead noise discrimination, an algorithm designed to expand the St. Jude Medical ShockGuard technology and provide sensing options designed to help reduce the incidence of inappropriate shocks for patients with these devices.
"For some patients, the fear of receiving a shock can either prevent them from receiving a potentially life-saving device, or cause anxiety that reduces their quality of life once they receive the device," said Eric S. Fain, MD, president of the St. Jude Medical cardiac rhythm management division, in the release. "These devices directly address this patient concern and provides physicians additional tools to manage individual patient needs. The launch of the Assura family of implantable defibrillators further strengthens our cardiac rhythm management product portfolio and provides physicians with the broadest range of options to deliver safe, effective therapy."
St. Jude Medical is headquartered in St. Paul, Minn.
Related Articles on FDA Approvals:
Hitachi Receives FDA Clearance for Echelon Oval MR System
Boston Scientific Announces FDA Approval for New Pacemakers
ProUroCare Receives FDA 510(k) Clearance for Prostate Imaging System